OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It is developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) comprising AUGMENT to improve the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment for boosting a woman's egg reserve by transferring the EggPCs from woman's own ovaries;...
215 First Street
Cambridge, MA 02142
Founded in 2011
OvaScience, Inc. Announces Resignation of David Harding, Chief Commercial Officer
Aug 27 15
On August 27, 2015, David Harding and OvaScience, Inc. mutually agreed that Mr. Harding will resign as Chief Commercial Officer of the company effective August 28, 2015 to pursue other opportunities.
OvaScience, Inc. - Special Call
Aug 10 15
To consider the publication of analyses of the AUGMENTSM treatment and other recent business updates, including geographic expansion
OvaScience Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 10 15
OvaScience reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company announced net loss of $17.5 million, or $0.64 per basic and diluted share, as compared to net loss of $9.9 million, or $0.42 per basic and diluted share, a year ago. The company announced revenues of $30,000, loss from operations of $17,174,000 compared to $9,595,000 a year ago. The increase in net loss is primarily attributable to stock-based compensation, planned higher personnel costs, and costs associated with the launch of the AUGMENT treatment in certain international IVF clinics.
For the six months the company announced revenues of $45,000, loss from operations of $33,987,000, net loss of $34,696,000 or $1.29 per basic and diluted share against loss from operations of $17,245,000, net loss of $17,707,000 or $0.83 per basic and diluted share compared to previous year.